Down 24% In A Month, Will Arvinas Stock Rebound?
Copyright 2022 Forbes Media LLC
business
2022-06-02 10:00:43

Clouds are reflected in windows at Arvinas Inc. headquarters in New Haven, Connecticut, U.S., on ... [+] Monday, Aug. 26, 2019. Photographer: George Etheredge/Bloomberg Â© 2019 Bloomberg Finance LP 
 AR VN RVN stock from one of the Wall Street analysts, citing development challenges for its cancer treatment - ARV-471. Larger pharmaceutical companies, Sanofi and Roche, have seen failures in their clinical trials for cancer treatments using oral selective estrogen receptor degraders (SERDs), raising investor concerns for Arvinas.
